Clinical Significance of Preoperative Albumin and Globulin Ratio in Patients with Gastric Cancer Undergoing Treatment

Mao, Minjie; Wei, Xiaoli; Sheng, Hui; Wang, Xueping; Li, Xiaohui; Liu, Yijun; Xing, Shan; Huang, Qi; Dai, Shuqin; Liu, Wanli

doi:10.1155/2017/3083267

Cited by 43 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to ALB and GLOB, the level of AGR was also analyzed. It has been reported that a low level of AGR has the potential to be a predictor for poor prognosis for breast cancer, gastric cancer, colorectal cancer, and lung cancer . However, in this study, the median of AGR was 1.5 (ranging from 0.6 to 2.3).…”

Section: Discussioncontrasting

confidence: 66%

Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer

Feng

Wang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

PurposeTo identify the pretreatment values of bilirubin and albumin and other serum biomarkers in predicting the prognosis for advanced pancreatic cancer.MethodsA total of 201 consecutive patients pathologically diagnosed as advanced pancreatic cancer were retrospectively reviewed. Tumor location, TNM classification, the level of baseline total bilirubin (TBIT), direct bilirubin (DBIT), albumin (ALB), globulin (GLOB), total protein (TP), ALB to GLOB ratio (AGR), CA19‐9, CA242, and CA50 were collected. The values of CA19‐9, CA242, and CA50 were divided into two groups according to the upper limit value which were 1000 U/mL, 150 IU/mL, and 500 IU/mL, respectively. The values of TBIL, DBIL, IBIL, ALB, GLOB, TP, ALB, and GLOB were divided into low and high groups according to the median. To investigate if the median was an effective discriminator in dividing these markers, the patients were divided into a test set (n = 100) and a validation set (n = 101). Kaplan‐Meier (K‐M) survival analysis and Cox regression analysis were performed to explore the potential relationship between them and overall survival (OS).ResultsA K‐M survival analysis revealed that the investigated markers in test set, including TBIL, DBIL, IBIL, ALB, GLOB, TP, ALB, and GLOB, were not associated with the OS. The findings from the validation set were consistent with those in the test set. Factors with P value smaller than 0.1 in the univariate analysis along with the tumor location, CA19‐9, CA242, CA50, were entered into the multivariate analysis. A Cox regression analysis suggested that the cancerization at head of pancreas (P = 0.01) and a high level of CA19‐9 (P = 0.02) were independent prognostic indicators for poor OS of pancreatic cancer.ConclusionsBaseline bilirubin and serum proteins were not associated with the prognosis of advanced pancreatic cancer. Tumor location and level of CA19‐9 may serve as significant indicators for poor prognosis in those patients.

show abstract

Section: Discussioncontrasting

confidence: 66%

Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer

Feng

Wang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The prognosis of GC is also related to the tumor microenvironment and the interaction between the tumor and the host environment; hence, nonanatomical prognostic factors cannot be neglected. To date, numerous nonanatomical prognostic factors for predicting the prognosis of patients with GC have been evaluated, such as neutrophil‐lymphocyte ratio, Glasgow Prognostic Score, and albumin‐to‐globulin ratio …”

Section: Introductionmentioning

confidence: 99%

Combination of preoperative plasma fibrinogen and AJCC staging improves the accuracy of survival prediction for patients with stage I‐II gastric cancer after curative gastrectomy

et al. 2019

View full text Add to dashboard Cite

This study aimed to determine the prognostic value of preoperative plasma fibrinogen concentration (PFC) in patients with stage I‐II gastric cancer after curative gastrectomy. The preoperative PFC and clinicopathological data of 793 patients with stage I‐II gastric cancer who underwent curative gastrectomy were analyzed retrospectively. PFC of <4.0 g/L and ≥4.0 g/L were considered as PFC0 and PFC1, respectively. The association between PFC and the clinicopathological features of gastric cancer and the value of PFC in survival prediction were investigated. PFC1 indicated poorer overall survival and cancer‐specific survival among patients with tumor‐node‐metastasis (TNM) stage I‐II, and PFC was identified as an independent indicator of survival via multivariate analysis. Importantly, PFC stage was proven to be an independent prognostic factor for stage I and T1‐4aN0 gastric cancer. PFC stage combined with the American Joint Committee on Cancer (AJCC)‐TNM stage has better accuracy for predicting disease prognosis than AJCC‐TNM stage alone. The prognosis of patients with stage I‐II gastric cancer can be further stratified by PFC level. For patients with stage I gastric cancer, PFC1 can be considered a high‐risk prognostic factor, and adjuvant chemotherapy should be recommended for patients with PFC1.

show abstract

“…suggested that small-cell lung cancer patients with a pretreatment serum AGR <1.29 had a 1.35 times higher risk of death than those with an AGR ≥1.29. Mao et al 45. showed that a serum AGR <1.50 indicated poorer overall survival in patients with gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade

Wang

Liu

et al. 2019

Asian J Androl

View full text Add to dashboard Cite

The pretreatment serum albumin/globulin ratio (AGR) has been used as a prognostic biomarker for various cancer types. However, the prognostic value of the AGR for prostate cancer, especially for metastatic prostate cancer (mPCa) after maximal androgen blockade (MAB), remains unclear. The aim of this study was to evaluate the prognostic value of the pretreatment serum AGR for mPCa treated with MAB. This retrospective study included 214 mPCa patients receiving MAB from October 2007 to March 2017. The correlation of the AGR with survival was estimated using Kaplan-Meier analysis and Cox proportional hazards models. The cutoff value of the AGR was 1.45 according to the receiver operating characteristic curve. Kaplan-Meier analysis demonstrated that patients with a low AGR (<1.45) had poor outcomes in terms of progression-free survival (PFS) and cancer-specific survival (CSS). Multivariate Cox analyses showed that the AGR was an independent predictor of PFS (hazard ratio [HR] = 0.642; 95% confidence interval [CI]: 0.430-0.957; P = 0.030) and CSS (HR = 0.412; 95% CI: 0.259-0.654; P < 0.001). Furthermore, in a subset of 79 patients with normal serum albumin levels (≥40.0 g l), the serum AGR remained an independent predictor of CSS (P = 0.009). The pretreatment AGR was an independent prognostic biomarker for PFS and CSS in patients with mPCa receiving MAB. In addition, the AGR remained effective for the prediction of CSS in patients with normal albumin levels (≥40 g l). However, further prospective studies are needed to confirm our conclusions.

show abstract

Clinical Significance of Preoperative Albumin and Globulin Ratio in Patients with Gastric Cancer Undergoing Treatment

Cited by 43 publications

References 34 publications

Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer

Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer

Combination of preoperative plasma fibrinogen and AJCC staging improves the accuracy of survival prediction for patients with stage I‐II gastric cancer after curative gastrectomy

Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade

Contact Info

Product

Resources

About